Codrituzumab (Anti-GPC3 / Glypican-3)

製品コードA2476 別名: GC33; RO5137382 純度：99%

Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 43800	国内在庫なし(納期7~10日)
1mg*5	JPY 118700	お問い合わせ
1mg*25	JPY 346200	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 5.678mg/ml 内毒素：＜1EU/mg

生物活性

製品説明	Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD.

製品説明

CAS No.	1365267-33-9
Molecular Weight	150 kDa
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07224568	NOT_YET_RECRUITING		Solid Tumor (Excluding CNS); Hepatocellular Carcinoma; Liver Cell Carcinoma; Liposarcoma; Yolk Sac Tumor; Rhabdomyosarcoma	Seattle Children's Hospital	2026-04-01	PHASE1
NCT07148050	RECRUITING		Solid Tumor (Excluding CNS); Liver Cell Carcinoma; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Liposarcoma; Rhabdomyosarcoma; Embryonal Sarcoma of Liver; Wilms Tumor; Hepatocellular Carcinoma; Hepatoblastoma	Seattle Children's Hospital	2025-12-22	PHASE1
NCT07795437	RECRUITING		Hepatocellular Carcinoma (HCC)	Peking University First Hospital	2026-08-25
NCT06968195	SUSPENDED	Drug: Cyclophosphamide\|Drug: Fludarabine	Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Refractory Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8	Roswell Park Cancer Institute	2026-07-15	PHASE1
NCT06198296	RECRUITING		Hepatoblastoma; Hepatocellular Carcinoma; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of Liver	Baylor College of Medicine	2025-06-10	PHASE1
NCT07164313	RECRUITING	Drug: ZW251	Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer; Germ Cell Tumor	Zymeworks BC Inc.	2025-10-21	PHASE1

(data from https://clinicaltrials.gov, updated on 2025-11-04)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須